The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novo Nordisk’s Wegovy (semaglutide) injection to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
This decision marks Wegovy as the first GLP-1 therapy cleared for MASH, strengthening Novo Nordisk’s foothold in the metabolic disease space. Until now, the only FDA-approved therapy for MASH was Rezdiffra (Madrigal Pharmaceuticals), approved in 2024.
Login to view more
